Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)

Abstract Background For resectable adenocarcinoma of the esophagogastric junction (AEG), current treatment exploration primarily focuses on perioperative chemotherapy regimens combined with PD-1/PD-L1 inhibitors, but the long-term survival benefits of still require further investigation, and the use...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingyi Li, Yuqin Cao, Xipeng Wang, Chengqiang Li, Liqin Zhao, Hecheng Li
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Cancer
Subjects:
Neoadjuvant immunochemotherapy
Perioperative Immunochemotherapy
Adenocarcinoma of esophagogastric junction
Immune checkpoint inhibitors
Efficacy and safety
Survival
Online Access:https://doi.org/10.1186/s12885-025-13589-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13589-z

Similar Items